Average common and common equivalent shares - diluted (in thousands)
37,500
37,326
37,231
37,005
36,900
Balance Sheet Data as of June 30:
2017
2016
2015
2014
2013
Cash, cash equivalents and short-term available-for-sale investments
157,714
$
95,835
$
110,921
$
363,354
$
332,937
Working capital
212,503
199,744
208,515
443,022
377,432
Total assets
1,558,219
1,129,581
1,063,360
862,491
778,098
Total shareholders' equity
949,627
879,280
846,935
795,265
737,541
Cash Flow Data:
2017
2016
2015
2014
2013
Net cash provided by operating activities
$
143,811
$
143,870
$
139,359
$
136,762
$
123,562
Capital expenditures
15,179
16,898
19,905
13,821
22,454
Cash dividends declared per share
1.28
1.28
1.27
1.23
1.18
Employee Data as of June 30:
2017
2016
2015
2014
2013
Employees
1,789
1,560
1,356
967
789
(1)
The Company acquired Space on July 1, 2016, and Advanced Cell Diagnostics on August 1, 2016.
(2)
The Company acquired Cliniqa on July 8, 2015, and Zephyrus on March 21, 2016.
(3)
The Company acquired Novus Biologicals on July 2, 2014, ProteinSimple on July 31, 2014, and CyVek on November 3, 2014.
(4)
The Company acquired Bionostics on July 22, 2013, and PrimeGene on April 30, 2014.
(5)
Earnings before income taxes included acquisition related expenses related to amortization of intangibles, costs recognized on sale of acquired inventories and professional fees associated with acquisition activity, as follows: 2017 - $73.2 million; 2016 - $37.6 million; 2015 - $37.6 million; 2014 - $20.0 million; 2013 - $10.2 million.
filings.tools